31 active not recruiting. 31 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Active not recruiting 31 |
| Phase 2 | 11 | Active not recruiting 11 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimers Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1060 | 2025-11-12 | 2026-09-25 |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimers Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1101 | 2025-09-17 | 2026-09-25 |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease, Huntingtons Disease | Phase 2 / Phase 3 | Active not recruiting | Skyhawk Therapeutics, Inc. | 120 | 2025-05-27 | 2026-05-01 |
| Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention Luci Coach-Assisted Intervention - Risk Behavior, Cognitive Decline | Phase 3 | Active not recruiting | LuciLab | 370 | 2025-03-13 | 2026-08-25 |
| Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. Turmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day - Cognitive Decline, Subjective Cognitive Impairment | Phase 2 / Phase 3 | Active not recruiting | Instituto Mexicano del Seguro Social | 100 | 2025-02-20 | 2026-03-25 |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD buntanetap/posiphen, Placebo - Early Alzheimers Disease | Phase 3 | Active not recruiting | Annovis Bio Inc. | 760 | 2025-02-04 | 2026-05-18 |
| A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) Remternetug, Placebo - Alzheimer's Disease | Phase 3 | Active not recruiting | Eli Lilly and Company | 1400 | 2024-10-24 | 2026-10-07 |
| Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD Ginkgo biloba extract 50 dropping pills, Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant - Mild Cognitive Impairment | Phase 2 / Phase 3 | Active not recruiting | Beijing Tiantan Hospital | 144 | 2024-09-27 | 2026-10-08 |
| DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease lecanemab - Alzheimer's Disease, Dementia | Phase 3 | Active not recruiting | Washington University School of Medicine | 40 | 2024-06-10 | 2026-07-27 |
| Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Xanamem, Placebo - Dementia Moderate, Dementia, Mild | Phase 2 / Phase 3 | Active not recruiting | Actinogen Medical | 247 | 2024-04-12 | 2026-10-21 |
| A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease LIPUS-Brain, Placebo - Alzheimer Disease, Early Onset | Phase 3 | Active not recruiting | Sound Wave Innovation CO., LTD. | 220 | 2023-10-31 | 2025-05-15 |
| A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) Donanemab, Placebo, Dexamethasone - Alzheimer's Disease, Dementia | Phase 3 | Active not recruiting | Eli Lilly and Company | 1175 | 2023-02-28 | 2026-06-18 |
| ACHIEVE Brain Health Follow-Up Study Hearing intervention, Successful aging/delayed hearing intervention - Aging, Cognitive Decline | Phase 3 | Active not recruiting | Johns Hopkins University | 629 | 2023-01-12 | 2026-07-21 |
| Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) AR1001, Placebo - Alzheimer Disease | Phase 3 | Active not recruiting | AriBio Co., Ltd. | 1535 | 2022-12-23 | 2026-10-14 |
| Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial Tranexamic Acid 100Mg/ml Inj Vial 10ml, Placebo - Surgical Site Infection, Dementia | Phase 3 | Active not recruiting | Bayside Health | 826 | 2022-11-01 | 2025-12-31 |
| A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Donanemab, Placebo - Alzheimer Disease, Dementia | Phase 3 | Active not recruiting | Eli Lilly and Company | 1500 | 2022-10-10 | 2026-09-22 |
| Preventing Cognitive Decline with Metformin Metformin XR, 500-2000mg nocte - Cognitive Decline | Phase 3 | Active not recruiting | Garvan Institute of Medical Research | 242 | 2022-07-15 | 2024-10-02 |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) E2814, Lecanemab, Matching Placebo (E2814) - Alzheimers Disease, Dementia | Phase 2 / Phase 3 | Active not recruiting | Washington University School of Medicine | 197 | 2021-12-22 | 2026-07-27 |
| A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II GNR-055 1.0-2.0-3.0 mg/kg, GNR-055 2.0 mg/kg, GNR-055 3.0 mg/kg - Mucopolysaccharidosis Type II, Metabolic Diseases | Phase 2 / Phase 3 | Active not recruiting | AO GENERIUM | 32 | 2021-11-30 | 2026-09-21 |
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease Deutetrabenazine - Huntington Disease | Phase 2 / Phase 3 | Active not recruiting | Vanderbilt University Medical Center | 30 | 2021-11-19 | 2026-08-05 |
Showing 20 of 31. Sign in to see all of them.
Alzheimer Disease (17) · Cognitive Dysfunction (13) · Dementia (11) · Delirium (3) · Mental Disorders (3) · Nervous System Diseases (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Huntington Disease (2) · Insulin Resistance (2) · Neoplasm Metastasis (2) · Neurodegenerative Diseases (2) · Plaque, Amyloid (2) · Psychomotor Agitation (2)
Mental Disorders (28) · Nervous System Diseases (24) · Brain Diseases (21) · Central Nervous System Diseases (21) · Neurodegenerative Diseases (18) · Tauopathies (16) · Cognition Disorders (14) · Dementia (12) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (7) · Neurologic Manifestations (6) · Pathologic Processes (6) · Dyskinesias (4) · Neurobehavioral Manifestations (4)
donanemab (4) · lecanemab (4) · Haloperidol (2) · Chlorpromazine (1) · Cognitive Training (1) · Dexamethasone (1) · Dexmedetomidine (1) · Escitalopram (1) · Gelatin (1) · Lorazepam (1) · Metformin (1) · Midazolam (1) · Saline Solution (1) · Tranexamic Acid (1) · UE2343 (1)
Eli Lilly and Company (5) · Washington University School of Medicine (3) · Hoffmann-La Roche (2) · M.D. Anderson Cancer Center (2) · Vanderbilt University Medical Center (2) · AO GENERIUM (1) · Actinogen Medical (1) · Annovis Bio Inc. (1) · AriBio Co., Ltd. (1) · Bayside Health (1) · Beijing Tiantan Hospital (1) · Capital Medical University (1) · Columbia University (1) · Eisai Inc. (1) · Garvan Institute of Medical Research (1)
United States (21) · Australia (12) · United Kingdom (11) · Canada (10) · Japan (9) · Spain (8) · China (7) · France (6) · Germany (6) · Italy (6) · Argentina (5) · Brazil (5) · Netherlands (5) · Poland (5) · Puerto Rico (5)
Randall J Bateman, MD (3) · David Hui (2) · Amy E Brown, MD (1) · Constantine Lyketsos, MD, MHS (1) · Frank R Lin, MD, PhD (1) · Heidi Smith, MD, MSCI (1) · Hiroaki Shimokawa (1) · James Rock (1) · Jianping Jia, MD,PhD (1) · Josef Coresh, MD, PhD (1)
PMID 42552749, PMID 31587995, PMID 32479786, PMID 36341846, PMID 36449413, PMID 36934371, PMID 37009976, PMID 37017737, PMID 37203336, PMID 37459141, PMID 38323738, PMID 38581616, PMID 38730496, PMID 38940656, PMID 39292433, PMID 39575854, PMID 39974075, PMID 40034530, PMID 40042496, PMID 40063015, PMID 40120616, PMID 40133524, PMID 40172303, PMID 40603145, PMID 40619285, PMID 40667684, PMID 40742738, PMID 40955720, PMID 40985290, PMID 41082199, PMID 41170658, PMID 41330788, PMID 41477670, PMID 41689888, PMID 41804324, PMID 42128444, PMID 42273802, PMID 42644303
R01AG046179 (2), R01AG053267 (2), R56AG053267 (2), U01AG042791 (2), U01AG059798 (2), 2018 (1), 2025 (1), R01AG052510 (1), R01AG062624 (1), R01AG068319 (1), R01AG070349 (1), R01AG076518 (1), R21NR016736 (1), R56AG058234 (1), R61HL151951 (1)